Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 181

Results For "AI"

8753 News Found

Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies
Biotech | November 10, 2025

Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies

The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies


Bristol Myers Squibb prices €5 billion senior unsecured notes offering
News | November 10, 2025

Bristol Myers Squibb prices €5 billion senior unsecured notes offering

The offering is expected to close on November 10, 2025, subject to customary closing conditions


Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
News | November 10, 2025

Venus Remedies expands ASEAN presence with new drug approvals in Vietnam

Venus Remedies now has 29 active product approvals in Vietnam alone


Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
Drug Approval | November 10, 2025

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'

The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy


Glenmark secures China approval for Ryaltris
Drug Approval | November 10, 2025

Glenmark secures China approval for Ryaltris

The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline


Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr
News | November 09, 2025

Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr

Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025


Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
News | November 09, 2025

Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr

Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025


Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr
News | November 09, 2025

Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr

Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025


Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
News | November 09, 2025

Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr

Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025